Artificial neural network modeling of antimycobacterial chemical space to introduce efficient descriptors employed for drug design

Abstract Tuberculosis has become a serious condition with an estimated 2 million deaths each year in the world. According to WHO report, multi-resistant tuberculosis is responsible for approximately 460 thousand recent cases per year and for about 740 thousand patients infected by both Mycobacterium tuberculosis and HIV/AIDS. In the current study, several bioactive structure databases were analyzed using cheminformatics tools to correlate the chemical structures of different compounds with their pharmacological activities; in addition, these tools were tried to identify molecules that could be candidate for experimental assays. In this regard, for defining the effective chemical compounds against Mycobacterium , a database consisting of 400 antimycobacterial compounds has been constructed. In the next step, more than 1400 molecular descriptors were defined by DRAGON application server for each compound. Then, the resulting descriptors were clustered by kNN and k-means clustering methods to be employed for ANN modeling. Utilizing PLS and ANN modeling methods led to building a model for predicting minimum inhibitory concentration (MIC) with R 2  = 0.98 and MSE = 0.0002. Applying the mentioned cheminformatics tools, it would be possible to design and introduce new compounds with broad applications in antimycobacterial drug discovery and development.

[1]  Anders Karlén,et al.  Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery. , 2008, Bioorganic & medicinal chemistry.

[2]  W. W. Barrow,et al.  Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. , 2004, Bioorganic & medicinal chemistry.

[3]  Mark J. Schreiber,et al.  Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. , 2008, Bioorganic & medicinal chemistry letters.

[4]  C. Bewley,et al.  Design and synthesis of substrate-mimic inhibitors of mycothiol-S-conjugate amidase from Mycobacterium tuberculosis. , 2007, Bioorganic & medicinal chemistry letters.

[5]  M. Daffé,et al.  Synthesis and evaluation of a novel series of pseudo-cinnamic derivatives as antituberculosis agents. , 2009, Bioorganic & medicinal chemistry letters.

[6]  S. Cannas,et al.  In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. , 2005, International journal of antimicrobial agents.

[7]  P. Yogeeswari,et al.  An atom economic synthesis and antitubercular evaluation of novel spiro-cyclohexanones. , 2009, Bioorganic & medicinal chemistry letters.

[8]  P. Yogeeswari,et al.  Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. , 2009, European journal of medicinal chemistry.

[9]  M. Everett,et al.  Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth. , 2007, Bioorganic & medicinal chemistry letters.

[10]  H. Drugeon,et al.  Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. , 2000, The Journal of antimicrobial chemotherapy.

[11]  Victor Lobanov,et al.  Using artificial neural networks to drive virtual screening of combinatorial libraries , 2004 .

[12]  A. Schüffler,et al.  Isolation, structure elucidation, and biological evaluation of the unusual heterodimer chrysoxanthone from the ascomycete IBWF11-95A , 2009 .

[13]  B. Meibohm,et al.  Discovery of novel isoxazolines as anti-tuberculosis agents. , 2007, Bioorganic & medicinal chemistry letters.

[14]  N. Lall,et al.  Antiviral and antituberculous activity of Helichrysum melanacme constituents. , 2006, Fitoterapia.

[15]  C. Townsend,et al.  In Vitro Activity of a Novel Antimycobacterial Compound, N-Octanesulfonylacetamide, and Its Effects on Lipid and Mycolic Acid Synthesis , 2001, Antimicrobial Agents and Chemotherapy.

[16]  N. Lall,et al.  Diospyrone, crassiflorone and plumbagin: three antimycobacterial and antigonorrhoeal naphthoquinones from two Diospyros spp. , 2009, International journal of antimicrobial agents.

[17]  L. Gundersen,et al.  Synthesis and antimycobacterial activity of 5-formylaminopyrimidines; analogs of antibacterial purines. , 2009, Bioorganic & medicinal chemistry letters.

[18]  Perumal Yogeeswari,et al.  5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. , 2009, Bioorganic & medicinal chemistry letters.

[19]  A. Kamal,et al.  Antitubercular agents. Part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents. , 2005, Bioorganic & medicinal chemistry letters.

[20]  F. Vergara,et al.  Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Derek S. Tan,et al.  Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. , 2008, Bioorganic & medicinal chemistry letters.

[22]  K. Srivastava,et al.  Substituted quinolinyl chalcones and quinolinyl pyrimidines as a new class of anti-infective agents. , 2009, European journal of medicinal chemistry.

[23]  M. Fauville-Dufaux,et al.  Antimycobacterial activity of synthetic pamamycins. , 2004, The Journal of antimicrobial chemotherapy.

[24]  J. Maugein,et al.  Synthesis and antitubercular activity of ferrocenyl diaminoalcohols and diamines. , 2008, Bioorganic & medicinal chemistry.

[25]  G. Besra,et al.  Platensimycin Activity against Mycobacterial β-Ketoacyl-ACP Synthases , 2009, PloS one.

[26]  A. Dimoglo,et al.  Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives. , 2007, Bioorganic & medicinal chemistry.

[27]  Adrian G. Barnett,et al.  Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet , 2009, PloS one.

[28]  C. Kaiser,et al.  Synthesis and in vitro antitubercular activity of a series of quinoline derivatives. , 2009, Bioorganic & medicinal chemistry.

[29]  P. Yogeeswari,et al.  A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles. , 2009, Bioorganic & medicinal chemistry letters.

[30]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[31]  S. Gibbons,et al.  Modulation of isoniazid susceptibility by flavonoids in Mycobacterium , 2008 .

[32]  D. Sriram,et al.  Antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. , 2008, International journal of antimicrobial agents.

[33]  W. Bishai,et al.  Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. , 1999, The Journal of antimicrobial chemotherapy.

[34]  N. Lounis,et al.  In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[35]  G. Besra,et al.  Arabinofuranose disaccharide analogs as inhibitors of Mycobacterium tuberculosis , 2003 .

[36]  J. Dimmock,et al.  N-Aroyl-3,5-bis(benzylidene)-4-piperidones: a novel class of antimycobacterial agents. , 2008, Bioorganic & medicinal chemistry.

[37]  Yves L Janin,et al.  Antituberculosis drugs: ten years of research. , 2007, Bioorganic & medicinal chemistry.

[38]  S. Franzblau,et al.  In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[39]  S. Dastidar,et al.  Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin , 2004 .

[40]  G. Besra,et al.  EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets , 2007, Antimicrobial Agents and Chemotherapy.

[41]  D. Minnikin,et al.  Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. , 2003, Bioorganic & medicinal chemistry letters.

[42]  Joel S. Freundlich,et al.  Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosis , 2009, ChemMedChem.

[43]  M. Cynamon,et al.  In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide , 1998, Antimicrobial Agents and Chemotherapy.

[44]  P. Madge,et al.  Synthesis and biological evaluation of galactofuranosyl alkyl thioglycosides as inhibitors of mycobacteria. , 2007, Carbohydrate research.

[45]  Kerly F. M. Pasqualoto,et al.  QSAR Modeling of a Set of Pyrazinoate Esters as Antituberculosis Prodrugs , 2010, Archiv der Pharmazie.

[46]  D. Sarkar,et al.  Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. , 2008, International journal of antimicrobial agents.

[47]  F. Baquero,et al.  In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. , 2006, International journal of antimicrobial agents.

[48]  Dhople Am In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans. , 2001 .

[49]  Mohamed Ashraf Ali,et al.  Synthesis and evaluation of phenoxy acetic acid derivatives as anti-mycobacterial agents , 2006 .

[50]  Shagufta,et al.  Diaryloxy methano phenanthrenes: a new class of antituberculosis agents. , 2004, Bioorganic & medicinal chemistry.

[51]  S. Cannas,et al.  [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. , 2007, Bioorganic & medicinal chemistry letters.

[52]  M. Radi,et al.  Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones. , 2009, Bioorganic & medicinal chemistry.

[53]  J. Kočí,et al.  Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents. , 2009, European journal of medicinal chemistry.

[54]  A. Gaikwad,et al.  Synthesis and antitubercular activities of bis-glycosylated diamino alcohols. , 2005, Bioorganic & medicinal chemistry.

[55]  E. Laurini,et al.  Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations. , 2009, Bioorganic & medicinal chemistry.

[56]  C. Townsend,et al.  New α-methylene-γ-butyrolactones with antimycobacterial properties , 2005 .

[57]  M. Şenel,et al.  Synthesis, characterization and antimicrobial activity of water soluble dendritic macromolecules. , 2009, European journal of medicinal chemistry.

[58]  S. Maitra,et al.  Principle Component Analysis and Partial Least Squares: Two Dimension Reduction Techniques for Regression , 2008 .

[59]  Vasyl Kovalishyn,et al.  Predictive QSAR modeling of phosphodiesterase 4 inhibitors. , 2012, Journal of molecular graphics & modelling.

[60]  Aldo Segura-Cabrera,et al.  Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening. , 2008, Bioorganic & medicinal chemistry letters.

[61]  R. Wallace,,et al.  Clinical Trial of Clarithromycin for Cutaneous (Disseminated) Infection due to Mycobacterium chelonae , 1993, Annals of Internal Medicine.

[62]  D. Muthas,et al.  Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[63]  J. Férriz,et al.  New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains. , 2009, Bioorganic & medicinal chemistry.

[64]  Ş. Küçükgüzel,et al.  Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. , 2002, Farmaco.

[65]  J. Chattopadhyaya,et al.  Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. , 2009, Bioorganic & medicinal chemistry.

[66]  A. Gaikwad,et al.  Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents. , 2004, Bioorganic & medicinal chemistry letters.

[67]  R. Meleddu,et al.  Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis. , 2009, International journal of antimicrobial agents.

[68]  L. M. Lima,et al.  Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides. , 2009, Bioorganic & medicinal chemistry.

[69]  Yoshifumi Yamamoto,et al.  Synthesis of new sugar derivatives from Stachys sieboldi Miq and antibacterial evaluation against Mycobacterium tuberculosis, Mycobacterium avium, and Staphylococcus aureus. , 2007, Bioorganic & medicinal chemistry letters.

[70]  P. Juréen,et al.  Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[71]  A. V. Adhikari,et al.  Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. , 2010, Bioorganic & medicinal chemistry letters.

[72]  S. Franzblau,et al.  Structure-activity relationships of macrolides against Mycobacterium tuberculosis. , 2008, Tuberculosis.

[73]  A. Misra,et al.  Synthesis and evaluation of antitubercular activity of glycosyl thio- and sulfonyl acetamide derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[74]  A. Okunade,et al.  Natural antimycobacterial metabolites: current status. , 2004, Phytochemistry.

[75]  J. Férriz,et al.  Salicylanilide esters of N-protected amino acids as novel antimicrobial agents. , 2009, Bioorganic & medicinal chemistry letters.

[76]  C. Wagner,et al.  Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. , 2005, Bioorganic & medicinal chemistry letters.

[77]  A. Fassihi,et al.  Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. , 2009, European journal of medicinal chemistry.

[78]  The metabolism of 2-methyladenosine in Mycobacterium smegmatis. , 2002, Microbiology.

[79]  P. Brennan,et al.  N-D-aldopentofuranosyl-N'-[p-(isoamyloxy)phenyl]-thiourea derivatives: potential anti-TB therapeutic agents. , 2008, Bioorganic & medicinal chemistry letters.

[80]  D. Ordway,et al.  Activity against Mycobacterium tuberculosis with concomitant induction of cellular immune responses by a tetraaza-macrocycle with acetate pendant arms. , 2001, Research in microbiology.

[81]  Ping Chen,et al.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. , 2005, The Journal of antimicrobial chemotherapy.

[82]  A. Monge,et al.  Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. , 2003, European journal of medicinal chemistry.

[83]  S. Cole,et al.  A new synthetic access to furo[3,2-f]chromene analogues of an antimycobacterial. , 2008, Bioorganic & medicinal chemistry.

[84]  I. Chopra,et al.  Antibacterial spectra of drugs used for chemotherapy of mycobacterial infections. , 1998, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[85]  S. Said-Fernández,et al.  Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. , 2007, Bioorganic & medicinal chemistry.

[86]  V. Labombardi,et al.  Ciprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex , 1993, Antimicrobial Agents and Chemotherapy.

[87]  S. Franzblau,et al.  Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[88]  A. Gaikwad,et al.  Baylis-Hillman reaction: convenient ascending syntheses and biological evaluation of acyclic deoxy monosaccharides as potential antimycobacterial agents. , 2002, Bioorganic & medicinal chemistry.

[89]  D. Chanda,et al.  Antitubercular potential of some semisynthetic analogues of phytol. , 2010, Bioorganic & medicinal chemistry letters.

[90]  J. D. Douglas,et al.  Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. , 2002, Microbiology.

[91]  Dong-Wan Koo,et al.  In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria. , 2008, International journal of antimicrobial agents.

[92]  A. Dimoglo,et al.  Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities. , 2005, Bioorganic & medicinal chemistry.

[93]  P. Yogeeswari,et al.  Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. , 2006, Bioorganic & medicinal chemistry letters.

[94]  Ying Zhang,et al.  Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. , 2007, Journal of medical microbiology.

[95]  P. Vohra,et al.  Cloning and characterization of CYP51 from Mycobacterium avium. , 2006, American journal of respiratory cell and molecular biology.

[96]  Ram Sagar,et al.  CP-MLR directed QSAR studies on the antimycobacterial activity of functionalized alkenols--topological descriptors in modeling the activity. , 2005, Bioorganic & medicinal chemistry.

[97]  J. Naismith,et al.  Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. , 2003, Bioorganic & medicinal chemistry letters.

[98]  G. Besra,et al.  Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall. , 2007, European journal of medicinal chemistry.

[99]  P. Yogeeswari,et al.  Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. , 2006, Bioorganic & medicinal chemistry.

[100]  H. Munier-Lehmann,et al.  Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity. , 2008, Bioorganic & medicinal chemistry.

[101]  rpoB Gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. , 2001, Emerging infectious diseases.

[102]  L. Toll,et al.  Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. , 2007, Bioorganic & medicinal chemistry letters.

[103]  J. Chattopadhyaya,et al.  Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. , 2009, Bioorganic & medicinal chemistry.

[104]  R. Miri,et al.  Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. , 2009, Bioorganic & medicinal chemistry.

[105]  R. Wallace,,et al.  In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria , 2006, Antimicrobial Agents and Chemotherapy.

[106]  R. Sood,et al.  Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. , 2005, International journal of antimicrobial agents.

[107]  P. Madge,et al.  Synthesis and evaluation of galactofuranosyl N,N-dialkyl sulfenamides and sulfonamides as antimycobacterial agents. , 2007, Bioorganic & medicinal chemistry letters.

[108]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[109]  J. Suwiński,et al.  Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles. , 2004, European journal of medicinal chemistry.

[110]  J. Klucik,et al.  Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. , 2004, Journal of medicinal chemistry.

[111]  Karel Waisser,et al.  N‐Benzylsalicylthioamides: Highly Active Potential Antituberculotics , 2009, Archiv der Pharmazie.

[112]  N. Sinha,et al.  Synthesis of 1-[3-(4-benzotriazol-1/2-yl-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-3-substituted-thiourea derivatives as antituberculosis agents. , 2006, European journal of medicinal chemistry.

[113]  Fabrizio Manetti,et al.  Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. , 2006, Journal of medicinal chemistry.

[114]  C. Bewley,et al.  Inhibition and kinetics of mycobacterium tuberculosis and mycobacterium smegmatis mycothiol-S-conjugate amidase by natural product inhibitors. , 2003, Bioorganic & medicinal chemistry.

[115]  R. Ahmad,et al.  Synthesis and bioevaluation of glycosyl ureas as alpha-glucosidase inhibitors and their effect on mycobacterium. , 2003, Bioorganic & medicinal chemistry.

[116]  A. Lenaerts,et al.  Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. , 2006, Bioorganic & medicinal chemistry letters.

[117]  A. Shafiee,et al.  Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1,3,4-thiadiazol-2-ylthio]propionates. , 2006, Bioorganic & medicinal chemistry letters.

[118]  R. Gozalbes,et al.  Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones. , 2006, European journal of medicinal chemistry.

[119]  C. Boojamra,et al.  Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class. , 2003, Bioorganic & medicinal chemistry letters.

[120]  S. Terashima,et al.  Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners. , 2008, Bioorganic & medicinal chemistry letters.

[121]  A. Gaikwad,et al.  A facile synthesis of alpha,alpha'-(EE)-bis(benzylidene)-cycloalkanones and their antitubercular evaluations. , 2009, European journal of medicinal chemistry.

[122]  A. Calderón,et al.  3-Farnesyl-2-hydroxybenzoic acid is a new anti-Helicobacter pylori compound from Piper multiplinervium. , 2006, Journal of ethnopharmacology.

[123]  L. Gundersen,et al.  Synthesis of indolizine derivatives with selective antibacterial activity against Mycobacterium tuberculosis. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[124]  Cristina R Ventura,et al.  Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family. , 2008, Journal of medicinal chemistry.

[125]  K. Pupek,et al.  Pyranocoumarin, a novel anti-TB pharmacophore: synthesis and biological evaluation against Mycobacterium tuberculosis. , 2006, Bioorganic & medicinal chemistry.

[126]  P. Yogeeswari,et al.  Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl)hydrazono]ethyl}phenyl)thiourea. , 2006, Bioorganic & medicinal chemistry letters.

[127]  W. Denny,et al.  A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. , 2008, Tuberculosis.

[128]  Kerly F. M. Pasqualoto,et al.  Fragment-based and classical quantitative structure–activity relationships for a series of hydrazides as antituberculosis agents , 2008, Molecular Diversity.

[129]  Roman Rosipal,et al.  Overview and Recent Advances in Partial Least Squares , 2005, SLSFS.

[130]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[131]  I. Sugawara,et al.  Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin. , 2009, Indian journal of experimental biology.

[132]  S. Cole,et al.  Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. , 2007, Bioorganic & medicinal chemistry.

[133]  C. Vilchèze,et al.  Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli , 2006, Antimicrobial Agents and Chemotherapy.

[134]  N. Lall,et al.  The potential of South African plants against Mycobacterium infections. , 2008, Journal of ethnopharmacology.

[135]  Yashpal Singh,et al.  NEURAL NETWORKS IN DATA MINING , 2014 .

[136]  N. H. Fischer,et al.  New perspectives on natural products in TB drug research. , 2005, Life sciences.

[137]  R. Wallace,,et al.  Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth , 1986, Journal of clinical microbiology.

[138]  R. Pompei,et al.  Antimycobacterial compounds. New pyrrole derivatives of BM212. , 2004, Bioorganic & medicinal chemistry.

[139]  P. Tonge,et al.  Inhibiting enoyl-ACP reductase (FabI) across pathogenic microorganisms by linear sesquiterpene lactones from Anthemis auriculata. , 2008, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[140]  P. Ortiz de Montellano,et al.  Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.

[141]  L. Bekker,et al.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[142]  F. Pavan,et al.  Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives. , 2009, Bioorganic & medicinal chemistry.

[143]  P. Hartman,et al.  Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone , 1996, Antimicrobial agents and chemotherapy.

[144]  M. Radi,et al.  Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis. , 2009, Bioorganic & medicinal chemistry letters.

[145]  G. Besra,et al.  Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall. , 2004, Bioorganic & medicinal chemistry letters.

[146]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[147]  S. Franzblau,et al.  Syntheses and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. , 2006, Bioorganic & medicinal chemistry letters.

[148]  A. Vaz,et al.  Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. , 2001, Biochemical pharmacology.